[{"address1": "Paasheuvelweg 25", "city": "Amsterdam", "zip": "1105 BP", "country": "Netherlands", "phone": "31 20 240 6000", "website": "https://www.uniqure.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.", "fullTimeEmployees": 209, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Klemt", "age": 51, "title": "CFO, Principal Financial Officer & GM of Amsterdam Site", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 679793, "exercisedValue": 0, "unexercisedValue": 282015}, {"maxAge": 1, "name": "Dr. Jeannette  Potts J.D., Ph.D.", "age": 62, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 738547, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Walid  Abi-Saab M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 946132, "exercisedValue": 0, "unexercisedValue": 268795}, {"maxAge": 1, "name": "Prof. Hugo  Katus", "title": "Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Amin  Abujoub Ph.D.", "title": "Chief Technical Operations Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard  Porter Ph.D.", "age": 56, "title": "Chief Business & Scientific Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 732169, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 4, "compensationRisk": 4, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 52.65, "open": 51.05, "dayLow": 49.2, "dayHigh": 55.11, "regularMarketPreviousClose": 52.65, "regularMarketOpen": 51.05, "regularMarketDayLow": 49.2, "regularMarketDayHigh": 55.11, "payoutRatio": 0.0, "beta": 0.134, "forwardPE": -17.748367, "volume": 11086436, "regularMarketVolume": 11086436, "averageVolume": 2671753, "averageVolume10days": 11153220, "averageDailyVolume10Day": 11153220, "bid": 53.95, "ask": 54.54, "bidSize": 5, "askSize": 5, "marketCap": 2979822848, "fiftyTwoWeekLow": 4.45, "fiftyTwoWeekHigh": 55.11, "allTimeHigh": 82.49, "allTimeLow": 3.73, "priceToSalesTrailing12Months": 207.84145, "fiftyDayAverage": 17.4093, "twoHundredDayAverage": 14.8759, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3124804864, "profitMargins": 0.0, "floatShares": 38737699, "sharesOutstanding": 54866930, "sharesShort": 8274589, "sharesShortPriorMonth": 9725041, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.1508, "heldPercentInsiders": 0.060749996, "heldPercentInstitutions": 0.96938, "shortRatio": 8.01, "shortPercentOfFloat": 0.1528, "impliedSharesOutstanding": 54866930, "bookValue": -0.073, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -198995008, "trailingEps": -3.9, "forwardEps": -3.06, "enterpriseToRevenue": 217.954, "enterpriseToEbitda": -21.339, "52WeekChange": 10.016227, "SandP52WeekChange": 0.1529237, "quoteType": "EQUITY", "currentPrice": 54.31, "targetHighPrice": 94.29926, "targetLowPrice": 27.262615, "targetMeanPrice": 64.94992, "targetMedianPrice": 64.80272, "recommendationMean": 1.30769, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 376974016, "totalCashPerShare": 6.871, "ebitda": -146439008, "totalDebt": 521956000, "quickRatio": 9.347, "currentRatio": 9.982, "totalRevenue": 14337000, "revenuePerShare": 0.277, "returnOnAssets": -0.15385, "returnOnEquity": -4.2746797, "grossProfits": -121873000, "freeCashflow": -111588128, "operatingCashflow": -173436992, "revenueGrowth": -0.527, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -7.90783, "financialCurrency": "USD", "symbol": "QURE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketChangePercent": -0.522559, "postMarketPrice": 54.0262, "postMarketChange": -0.283802, "regularMarketChange": 1.66, "regularMarketDayRange": "49.2 - 55.11", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2671753, "fiftyTwoWeekLowChange": 49.86, "fiftyTwoWeekLowChangePercent": 11.204495, "fiftyTwoWeekRange": "4.45 - 55.11", "fiftyTwoWeekHighChange": -0.79999924, "fiftyTwoWeekHighChangePercent": -0.014516408, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1391610600000, "priceEpsCurrentYear": -19.910328, "fiftyDayAverageChange": 36.900703, "fiftyDayAverageChangePercent": 2.1195972, "twoHundredDayAverageChange": 39.4341, "twoHundredDayAverageChangePercent": 2.6508715, "priceToBook": -743.97266, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "shortName": "uniQure N.V.", "longName": "uniQure N.V.", "corporateActions": [], "postMarketTime": 1758931166, "regularMarketTime": 1758916800, "exchange": "NMS", "messageBoardId": "finmb_171029664", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "regularMarketChangePercent": 3.1529, "regularMarketPrice": 54.31, "fiftyTwoWeekChangePercent": 1001.6227, "earningsTimestamp": 1753792200, "earningsTimestampStart": 1753792200, "earningsTimestampEnd": 1753792200, "earningsCallTimestampStart": 1753792200, "earningsCallTimestampEnd": 1753792200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.9, "epsForward": -3.06, "epsCurrentYear": -2.72773, "displayName": "uniQure", "trailingPegRatio": null, "__fetch_time": "2025-09-27"}]